For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 18,153 | |||
| General and administrative | 9,421 | |||
| Operating loss | -27,574 | |||
| Finance income | 1,132 | |||
| Net loss | -26,442 | |||
| Effect of warrants modification, see note 6 | 2,429 | |||
| Total net loss attributable to common shareholders | -28,871 | |||
| Basic EPS | -1.32 | |||
| Diluted EPS | -1.32 | |||
| Basic Average Shares | 21,812,716 | |||
| Diluted Average Shares | 21,812,716 | |||
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)